HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions.

Abstract
To determine the efficacy of infliximab treatment in refractory posterior uveitis in Behçet's disease after withdrawal of infusions. Four patients with posterior uveitis secondary to Behçet's disease were treated with infliximab until complete remission and were followed after withdrawal of infusions. Intra-ocular inflammation was assessed using the binocular indirect ophthalmoscopy score, best-corrected visual acuity (BCVA) and foveal thickness measured by optic coherence tomography (OCT). All the patients included in the study were treated with infliximab for a minimum of 12 months and were in complete remission. None of the patients were taking steroids or immunosuppressants. Main follow-up after withdrawal of infusions was 7.5 months. Two out of four patients (50%) maintained complete remission of posterior uveitis. BCVA was stable in seven eyes. OCT showed worsening in macular edema in the two eyes of the patients with reactivation. Infliximab is an efficient long-term treatment for refractory posterior uveitis. Repeated infusions are required to maintain long-term remission which may be sustained on discontinuation of the drug.
AuthorsAlfredo Adán, Victoria Hernandez, Santiago Ortiz, Juan Jose Molina, Laura Pelegrin, Gerard Espinosa, Raimon Sanmartí
JournalInternational ophthalmology (Int Ophthalmol) Vol. 30 Issue 5 Pg. 577-81 (Oct 2010) ISSN: 1573-2630 [Electronic] Netherlands
PMID20490893 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
Topics
  • Adult
  • Antibodies, Monoclonal (administration & dosage)
  • Behcet Syndrome (drug therapy, physiopathology)
  • Female
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Infliximab
  • Infusions, Intravenous
  • Male
  • Recurrence
  • Remission Induction
  • Tumor Necrosis Factor-alpha (immunology)
  • Uveitis, Posterior (drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: